Tag: biologics

Displaying 1 - 20 of 27 results.

Pages

Danaher Corporation has agreed to divest assets to settle Federal Trade Commission charges that its proposed $21.4 billion acquisition of General Electric’s biopharmaceutical business, GE Biopharma, would violate federal antitrust law.
The Federal Trade Commission in collaboration with the Food and Drug Administration held a public workshop, "FDA/FTC Workshop on a Competitive Marketplace for Biosimilars." The purpose of the public workshop was to discuss FDA and FTC’s collaborative efforts to support appropriate...
On March 9, 2020, the Federal Trade Commission and the Food and Drug Administration will co-sponsor a public workshop on promoting competition in biologics markets. The workshop will be held at the FDA’s White Oak Campus in Silver Spring, Maryland and will also be webcast.
Federal Trade Commission Chairman Joseph J. Simons today joined Food and Drug Administration Commissioner Stephen Hahn in signing a joint statement promoting competition in biologics markets.
Following a public comment period, the Federal Trade Commission has approved a final order settling charges that Bristol-Myers Squibb Company’s proposed $74 billion acquisition of Celgene Corporation would violate federal antitrust law.
Pharmaceutical and biologic manufacturers Bristol-Myers Squibb Company, or BMS, and Celgene Corporation have agreed to divest Celgene’s Otezla, the most popular oral treatment in the United States for moderate-to-severe psoriasis, for $13.4 billion. This divestiture would settle Federal Trade...
WHAT:The Federal Trade Commission will host a workshop, “Understanding Competition in Prescription Drug Markets: Entry and Supply Chain Dynamics”. Acting FTC Chairman Maureen K. Ohlhausen and U.S. Food and Drug Commissioner Dr.
The number of reverse-payment patent settlements entered into by pharmaceutical companies in fiscal year 2015 declined from fiscal year 2014, marking a second annual decrease in such settlements, according to a new FTC staff report.
The Federal Trade Commission has announced an agenda for its upcoming workshop on competition issues related to prescription drug markets. The workshop, titled “Understanding Competition in Prescription Drug Markets: Entry and Supply Chain Dynamics,” will take place on November 8, 2017 at the FTC’s...
The Federal Trade Commission will hold a workshop on November 8, 2017 entitled, “Understanding Competition in Prescription Drug Markets: Entry and Supply Chain Dynamics.” Acting FTC Chairman Maureen K. Ohlhausen and U.S. Food and Drug Commissioner Dr. Scott Gottlieb will give the keynote addresses.
A few minutes ago, FTC Chairwoman Edith Ramirez delivered opening remarks to kick off today’s FTC workshop exploring emerging issues affecting competition and patient access to biologic medicines. You can view a live webcast of the workshop on the FTC’s website, or follow live tweets...
The Federal Trade Commission is hosting a workshop on competition issues surrounding biologics and follow-on biologic medicines on Feb. 4, 2014, in Washington, DC, and invites live webcast viewers to submit questions to moderators online.
Tomorrow, the FTC will host a workshop to explore emerging issues affecting competition and consumer access to biologic medicines.
The Federal Trade Commission today issued the final agenda for its one-day public workshop on competition and follow-on biologics, which will be held on February 4 at its Conference Center located at 601 New Jersey Ave., NW, in Washington, DC.
The Federal Trade Commission announced its one-day public workshop on competition and follow-on biologics has been rescheduled for Feb. 4, 2014. The workshop will be held at the FTC’s Conference Center located at 601 New Jersey Ave., NW, in Washington, and will examine competition issues...
Due to inclement weather and the closure of the federal government for today, the Federal Trade Commission has postponed until further notice its one-day public workshop on Follow-On Biologics: Impact of Recent Legislative and Regulatory Naming Proposals on Competition.
When faced with a major illness, patients usually want the best medicine available, regardless of cost. In some cases, next-generation “biologic” medicines may be the best treatments available. Unfortunately, these critical treatments can be very expensive. For example, Herceptin,...

Pages